Chong Kun Dang Pharmaceutical Corp. (KOSE:A185750) announces a share repurchase program. Under the program, the company will repurchase up to KRW 5,000 million worth of its shares, pursuant to a trust contract with Samsung Securities Co., Ltd. The purpose of the program is to stabilize stock price and enhance the value of shareholders.

The program will expire on October 16, 2023. As of October 12, 2022, the company had 318,897 shares in treasury within scope available for dividend and had 47,773 shares in treasury under other acquisitions.